A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel

Launched by TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL · Jun 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new device called a real-time pressure controller, which aims to help prevent nerve damage (known as peripheral neuropathy) caused by a common breast cancer treatment called albumin-paclitaxel. Peripheral neuropathy can be a painful and uncomfortable side effect that sometimes leads patients to stop their chemotherapy. The new device is designed to apply pressure in a way that gradually decreases from the toes and fingers to the wrists and limbs, which may help reduce this nerve damage more effectively than current methods.

If you're considering joining this trial, you need to be between 18 and 75 years old and in generally good health, with no prior history of chemotherapy or peripheral neuropathy. Participants will receive the new pressure controller while undergoing albumin-paclitaxel treatment, and they will be monitored for any changes in their symptoms. This trial is particularly important because it could lead to better management of side effects, allowing more patients to complete their chemotherapy successfully.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntarily signed written informed consent;
• • 2. Age ≥18 years and ≤75 years at enrollment, male or female patients;
• • 3. Eastern Cooperative Oncology Group (ECOG) physical status score of 0 or 1;
• • 4. Suitable for albumin-paclitaxel antitumor therapy;
• • 5. Cardiopulmonary, hepatic, renal, and coagulation functions are basically normal.
• Exclusion Criteria:
• • 1. Patients with prior chemotherapy;
• • 2. Patients with a prior diagnosis of peripheral neuropathy;
• • 3. Patients with a prior diagnosis of associated comorbidities (e.g., diabetes mellitus).